Interaction of serum proteins with CYP isoforms in human liver microsomes: Inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6

Life Sciences

Volumn 72, Issue 17, 2003, Pages 1953-1962

  Xu, Bang Qian ^a   Ishii, Mikio ^a   Ding, Li Rong ^a   Fischer, Nancy E ^a   Inaba, Tadanobu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

CYP2C19; CYP2D6; Free drug hypothesis; Human and bovine albumin; Serum proteins; and globulins; 1 acid glycoprotein (AGP)

Indexed keywords

ALPHA GLOBULIN; BOVINE SERUM ALBUMIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DEBRISOQUINE; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN; ISOENZYME; MEPHENYTOIN; OROSOMUCOID; PLASMA PROTEIN;

ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SUBSTRATE COMPLEX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; PREDICTION; PROTEIN PROTEIN INTERACTION;

BOVINAE;

EID: 0037436746     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00093-6     Document Type: Article

References (24)

1. Tillement J.P., Urien S., Chaumet-Riffaud P., Riant P., Bree F., Morin D., Albengres E., Barre J. Blood binding and tissue uptake of drugs. Recent advances and perspectives. Fundam Clin Pharmacol. 2:1988;223-238.
2. Ludden L.K., Ludden T.M., Collins J.M., Pentikis H.S., Strong J.M. Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: Implications for clinical correlation. J Pharmacol Exp Ther. 282:1997;391-396.
3. Carlile D.J., Hakooz N., Bayliss M.K., Houston J.B. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol. 47:1999;625-635.
4. Levy R., Qiu W., Yao C., Mather G., Kharasch E., Kunze K., Trager W., Carlson S., Ragueneau-Majlessi I. Relevance of the free drug hypothesis in the prediction of inhibition drug interactions from in vitro data. Drug Metab Rev. 32(Suppl 2):2000;154.
5. Hooper W.D., Sutherland J.M., Bochner F., Tyrer J.H., Eadie M.J. The effect of certain drugs on the plasma protein binding of phenytoin. Aust N Z J Med. 3:1973;377-381.
6. Tremaine L.M., Wilner K.D., Preskorn S.H. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet. 32(Suppl 1):1997;31-36.
7. Ishii M., Xu B.Q., Ding L.R., Fischer N.E., Inaba T. Interaction of plasma proteins with cytochrome P450 mediated metabolic reactions: Inhibition by human serum albumin and a-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat. Toxicol Letters. 119:2001;219-225.
8. Ortiz de Montellano P.R. Cytochrome 450: structure, mechanism, and biochemistry. 2nd ed. 1995;Plenum Press, New York.
9. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42.
10. Küpfer A., Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 26:1984;753-759.
11. Inaba T., Jurima M., Nakano M., Kalow W. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clin Pharmacol Ther. 36:1984;670-676.
12. De Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 46:1994;594-598.
13. Küpfer A., Desmond P.V., Schenker S., Branch R.A. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J Pharmacol Exp Ther. 221:1982;590-597.
14. Medina M.A., Giachetti A., Shore P.A. On the physiological disposition and possible mechanism of the antihypertensive action of debrisoquine. Biochem Pharmacol. 18:1969;891-901.
15. Peters K.P., Fauck J., Frömmel C. The automatic search for ligand binding sites in proteins of known three-dimensional structure using only geometric criteria. J Mol Biol. 256:1996;201-213.
16. Kosa T., Maruyama T., Otagiri M. Species differences of serum albumins: I. Drug binding sites. Pharm Res. 14:1997;1607-1612.
17. Sumida A., Kinoshita K., Fukuda T., Matsuda H., Yamamoto I., Inaba T., Azuma J. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem Biophys Res Comm. 262:1999;499-503.
18. Inaba T., Fischer N.E., Riddick D.S., Stewart D.J., Hidaka T. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin. KRM-1648, in human liver microsomes. Toxicol Lett. 93:1997;215-219.
19. Putnam F.W. The Plasma Proteins: Structure, Function, and Genetic control. 1975;Academic Press, New York.
20. Benet L.Z., Oie S., Schwartz J.B. Design and optimization of dosage regiments: pharmacokinetic data. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. 1996;1707-1792 McGraw-Hill, New York.
21. Ryan D.E., Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. Kalow W. Pharmacogenetics of Drug Metabolism. 1992;453-547 Pergamon Press, New York.
22. Ko J.W., Sukhova N., Thacker D., Chen P., Flockhart D.A. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 25:1997;853-862.
23. Otton S.V., Inaba T., Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 34(1):1984;73-80.
24. Williams J.A., Ring B.J., Cantrell V.E., Jones D.R., Eckstein J., Ruterbories K., Hamman M.A., Hall S.D., Wrighton S.A. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Disp. 30:2002;883-891.